1 / 10

Presented by Dr Heather Murray GPEP1 Registrar on behalf of

Does screening for CRC with FOBT reduce overall mortality? OTC FOBT kits – how to advise patients?. Presented by Dr Heather Murray GPEP1 Registrar on behalf of Dr Prakash Appanna, Dr Vinodha Naidoo, Dr Shadi Gadalla and Dr Heather Murray.

xaria
Download Presentation

Presented by Dr Heather Murray GPEP1 Registrar on behalf of

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Does screening for CRC with FOBT reduce overall mortality? OTC FOBT kits – how to advise patients? Presented by Dr Heather Murray GPEP1 Registrar on behalf of Dr Prakash Appanna, Dr Vinodha Naidoo, Dr Shadi Gadalla and Dr Heather Murray (C) August 2011 - Onewa Road Doctors Limited presented to the 2011 Conference for General Practice, Auckland, NZ

  2. METHODS Literature review 'Summon' database Information from Enterix producers of Insure FOB Test Visit & phone discussion pharmacies selling kit Personal correspondence labtests chemical pathologist Aims and Methods AIMS 1) Review evidence base for test 2) How to advise patients on OTC Screening Test Kits 3) Effect of FOBT screening on overall mortality (C) August 2011 - Onewa Road Doctors Limited presented to the 2011 Conference for General Practice, Auckland, NZ

  3. High rates in NZ and rest of world, especially >50 years and males Earlier detection = better outcomes FOBT is the method with the most research available on population screening No screening programme in NZ yet – but pilot study due to start in WDHB soon Why screen for CRC? (C) August 2011 - Onewa Road Doctors Limited presented to the 2011 Conference for General Practice, Auckland, NZ

  4. Immunochemical test shows better performance – but no test = 100% sensitive or specific Test available in pharmacies for $60 (InSure iFOBT), not through labtests Recommended for patients >50 years Concerns about the information presented to the public FOBT performance (C) August 2011 - Onewa Road Doctors Limited presented to the 2011 Conference for General Practice, Auckland, NZ

  5. FOBT screening can prevent 1 in 6 CRC deaths No trials demonstrate reduction in overall mortality Some suggest increased mortality – controversial Recommend further research into this Note no trial data for effect on mortality of iFOBT Effect on mortality? (C) August 2011 - Onewa Road Doctors Limited presented to the 2011 Conference for General Practice, Auckland, NZ

  6. Colonoscopy complications - perforation, bleeding, surgery, death Pilot studies demonstrated low complication rates – under trial conditions in 'expert centres' False positives and anxiety Need to consider whether benefit outweighs potential risk – selected populations eg >50yrs What about harms of screening? (C) August 2011 - Onewa Road Doctors Limited presented to the 2011 Conference for General Practice, Auckland, NZ

  7. Ensure patients are fully informed – risks and benefits, interpretation of results Access to colonoscopy – will they qualify if positive? Bottomline = informed choice How to advise patients? (C) August 2011 - Onewa Road Doctors Limited presented to the 2011 Conference for General Practice, Auckland, NZ

  8. 1) Direct to consumer screening is not the same as an organised national screening programme - why does the patient want the test? 2) Positive test does not necessarily = CRC or eligibility for public colonoscopy - false positives + negatives - Auckland regional colonoscopy guidelines do not include asymptomatic patients <50yrs with no risk factors or family history 3) No evidence of reduction in overall mortality, with potential increase 4) Proposed iFOBT for NZ screening has limited evidence to demonstrate effect on mortality Key Messages (C) August 2011 - Onewa Road Doctors Limited presented to the 2011 Conference for General Practice, Auckland, NZ

  9. 1) Ballinger et al, “Colorectal Cancer”, BMJ 2007;335:715-8. 2) Shaw et al, “Next steps for a feasibility study for colorectal cancer screening in New Zealand: Report for the Ministry of Health”, Department of Public Health, University of Otago, Wellington, 2008. 3) Zhu et al, “Comparsion of immunochemical and guaiac-based fecal occult blood test in screening and surveillance for advanced colorectal neoplasms: A meta-analysis”, Journal of Digestive Diseases 2010;11;148-160. 4) Personal correspondence with Dr Jeffrey Barron, chemical pathologist at LabTests Auckland. 5) Labtests patient instructions http://www.labtests.co.nz/Images-%281%29/PCS-PI-010---Faecal-Occult-Blood-Test.aspx 6) Hol et al, “Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy”, Gut 2010;59:62-68. 7) Smith et al, “Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia”, Cancer 2006;107;9:2152-2158. 8) Towler et al, “A systemic review of the effects of screening for colorectal cancer using the faecal occult blood test, Hemoccult”, BMJ 1998;317:559-65. References (C) August 2011 - Onewa Road Doctors Limited presented to the 2011 Conference for General Practice, Auckland, NZ

  10. 9) Rembold, “Number needed to screen: development of a statistic for disease screening”, BMJ 1998;317:307-12. 10) BowelScreen Aotearoa health professional information http://www.bowelscreenaotearoa.org/bca/index.php?option=com_content&view=article&id=407&Itemid=557 11) Hewitson et al, “Screening for colorectal cancer using the faecal occult blood test, Hemoccult”, Cochrane Database of Systematic Reviews 2007, Issue 1. Art.No.:CD001216. DOI: 10.1002/14651858.CDO001216.pub2. (2011 update). 12) Moayyedi et al, “Does fecal occult blood testing really reduce mortality? A reanalysis of systematic review data” Am J Gastroenterol 2006;101:380–384. 13) Zappa et al, “Letters to the editor: “Does fecal occult blood testing really reduce mortality? A reanalysis of systematic review data” and author's response”, Am J Gastroenterol 2006;101:2433-2434. 14) Colorectal Cancer Screening Advisory Group, “Report of the Colorectal Cancer Screening Advisory Group”, Ministry of Health 2006;1-160. 15) Lindholm et al, “Worry associated with Screening for Colorectal Carcinomas”, Scand J Gastrocntcrol 1997;32:238-245. 16) WHO criteria for screening, http://www.nt.gov.au/health/healthdev/health_promotion/bushbook/volume1/screening2.html References (contd)‏ (C) August 2011 - Onewa Road Doctors Limited presented to the 2011 Conference for General Practice, Auckland, NZ

More Related